A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

NCT07431866 | Recruiting Phase 1 FDA Drug

• 1 other identifier: 2828-005
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin

  Blood samples will be collected to determine the AUC0-inf of rosuvastatin.

  At designated time points (up to approximately 2 weeks)

• Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Furosemide

  Blood samples will be collected to determine the AUC0-inf of furosemide.

  At designated time points (up to approximately 2 weeks)

Secondary Outcomes (16)

• Number of Participants Who Experience an Adverse Event (AE)

  Up to approximately 1 month

• Number of Participants Who Discontinue Study Treatment Due to an AE

  Up to approximately 2 weeks

• Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Rosuvastatin

  At designated time points (up to approximately 2 weeks)

• Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Furosemide

  At designated time points (up to approximately 2 weeks)

• Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Rosuvastatin

  At designated time points (up to approximately 24 hours)

Study Arms (2)

Rosuvastatin + MK-2828

EXPERIMENTAL

Participants receive rosuvastatin and MK-2828 orally.

Drug: Rosuvastatin; Drug: MK-2828

Furosemide + MK-2828

EXPERIMENTAL

Participants receive furosemide and MK-2828 orally.

Drug: Furosemide; Drug: MK-2828

Interventions

Rosuvastatin DRUG

Oral administration

Rosuvastatin + MK-2828

Furosemide DRUG

Oral administration

Furosemide + MK-2828

MK-2828 DRUG

Oral administration

Furosemide + MK-2828; Rosuvastatin + MK-2828

Eligibility Criteria

• Age: 24 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2

You may not qualify if:

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Has a history of cancer (malignancy)

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Study Sites (1)

Fortrea Clinical Research Unit Inc ( Site 0001)

Daytona Beach, Florida, 32117, United States

RECRUITING

Related Links

• Merck Clinical Trials Information

MeSH Terms

Interventions

Rosuvastatin Calcium; Furosemide

Intervention Hierarchy (Ancestors)

Sulfonamides; Amides; Organic Chemicals; Fluorobenzenes; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hydrocarbons; Sulfones; Sulfur Compounds; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Sulfanilamides; Aniline Compounds; Amines

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Central Study Contacts

Toll Free Number

CONTACT

1-888-577-8839; Trialsites@msd.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 19, 2026
• First Posted: February 25, 2026
• Study Start: March 18, 2026
• Primary Completion (Estimated): June 7, 2026
• Study Completion (Estimated): June 7, 2026
• Last Updated: March 25, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share

Locations

US (1)